US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Lineage Cell Therapeutics (NYSE:LCTX), Inc. (NYSE American:LCTX) announced Wednesday that shareholders approved all proposals presented at the company’s annual meeting held last Thursday.
According to a press release statement based on the company’s SEC filing, all seven board nominees were re-elected to serve until the 2026 annual meeting. The directors re-elected are Michael H. Mulroy, Dipti Amin, Deborah Andrews, Angus C. Russell, Neal C. Bradsher, Brian M. Culley, and Anula Jayasuriya. Each nominee received at least 98.5 million votes in favor, with votes withheld ranging from approximately 1.1 million to 1.9 million.
Shareholders also ratified the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The motion received 158,952,692 votes in favor, 912,282 against, and 436,010 abstentions.
In an advisory vote, shareholders approved the compensation for the company’s named executive officers, with 96,071,162 votes for, 3,804,451 against, and 611,814 abstentions.
Additionally, shareholders approved an amendment to the company’s 2021 Equity Incentive Plan, increasing the number of common shares available for issuance by 19,500,000. The amendment passed with 88,575,737 votes in favor, 11,560,925 against, and 350,765 abstentions.
The company’s common shares are listed on the NYSE American under the symbol LCTX.
This information is based on a press release statement and details disclosed in the company’s recent SEC filing.
In other recent news, Lineage Cell Therapeutics reported positive 36-month results from a Phase 1/2a clinical study of its RG6501 (OpRegen) cell therapy for geographic atrophy secondary to age-related macular degeneration. The data, presented at the Clinical Trials at the Summit 2025, indicated that patients maintained improvements in vision and retinal structure for at least three years following a single administration. H.C. Wainwright reiterated its Buy rating and $9.00 price target on the stock after Roche, a partner of Lineage, presented promising three-year follow-up data from the same study. The data highlighted continued efficacy with just a single infusion of cells, which was noted as a significant differentiation from existing treatments.
Additionally, Lineage announced a change in its independent registered public accounting firm following the merger of Moss Adams LLP with Baker Tilly US, LLP. The company’s Audit Committee approved Baker Tilly as the new auditor for the fiscal year ending December 31, 2025. In another development, Lineage successfully completed a production run for two product candidates using a current Good Manufacturing Practice (cGMP) cell banking system. This achievement underscores the company’s ability to manufacture a scalable and consistent supply of cell-based products, although Lineage cautions about potential risks in the manufacturing process. All these developments were disclosed in filings with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.